Technical Analysis for BIT - Biotron Limited
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Death Cross | Bearish | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Gapped Down | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% |
Alert | Time |
---|---|
Lower Bollinger Band Support | 2 days ago |
Down 3% | 2 days ago |
Down 2% | 2 days ago |
Down 1% | 2 days ago |
Down 5% | 3 days ago |
Free Daily (Stock) Chart Reading
Biotron Limited Description
Biotron Limited is an Australia-based biotechnology company. The Company is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The Company is focused on the ongoing clinical development of its antiviral platform. The Company's lead antiviral drug, BIT225 is in mid-stage clinical development with approximately eight clinical trials completed. The Company has conducted clinical trails in human immunodeficiency virus-1 (HIV-1), hepatitis C virus (HCV) and HIV-1/HCV co-infected population. The clinical trials showed that BIT225 targets and reduces levels of HIV-1 residing in long-lived monocyte/macrophage reservoirs. BIT225 has clinical antiviral activity against both HIV-1 and HCV. BIT225 is pan-genotypic and is active against all HCV genotypes, including GT3. The Company designs and develops drugs that target a class of virus protein known as viroporins. Its earlier stage programs include Dengue, Influenza and others.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Media Biotechnology Drugs Flu Clinical Trial Protein Microbiology Hepatitis Siding Virus
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 0.125 |
52 Week Low | 0.024 |
Average Volume | 2,484,779 |
200-Day Moving Average | 0.073 |
50-Day Moving Average | 0.073 |
20-Day Moving Average | 0.068 |
10-Day Moving Average | 0.061 |
Average True Range | 0.005 |
RSI (14) | 29.08 |
ADX | 26.83 |
+DI | 22.504 |
-DI | 30.700 |
Chandelier Exit (Long, 3 ATRs) | 0.096 |
Chandelier Exit (Short, 3 ATRs) | 0.066 |
Upper Bollinger Bands | 0.086 |
Lower Bollinger Band | 0.051 |
Percent B (%b) | 0.1 |
BandWidth | 51.830 |
MACD Line | -0.006 |
MACD Signal Line | -0.004 |
MACD Histogram | -0.0017 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.057 | ||||
Resistance 3 (R3) | 0.057 | 0.055 | 0.057 | ||
Resistance 2 (R2) | 0.055 | 0.055 | 0.056 | 0.056 | |
Resistance 1 (R1) | 0.055 | 0.054 | 0.055 | 0.055 | 0.056 |
Pivot Point | 0.053 | 0.053 | 0.054 | 0.054 | 0.053 |
Support 1 (S1) | 0.053 | 0.053 | 0.053 | 0.053 | 0.052 |
Support 2 (S2) | 0.051 | 0.052 | 0.052 | 0.052 | |
Support 3 (S3) | 0.051 | 0.051 | 0.052 | ||
Support 4 (S4) | 0.051 |